Professor Gilles SALLES
Hospices Civils de Lyon,
Centre Hospitalier Lyon-Sud, Pierre Bénite, France

0Days0Hours0Minutes0Seconds

EDITORIAL

The development of genetically engineered T-cells constitutes a powerful new class of therapeutic agents that offers a new hope for cancer patients.

CAR T-cells in acute leukemia and diffuse large B-cell lymphoma were recently approved by the FDA and EMA and more than one hundred clinical trials are ongoing. This is definitely an emerging therapeutic breakthrough.

The aim of the Cell Therapy Innovation 360° (CTI 360°) congress is to become a reference in cell-therapy perspectives and issues in Onco-hematology issues. CTI 360° will bring together all the key French and European players in the field on May 21 and 22, 2019, in Lyon, France. [...]

GOALS

Understand the
MECHANISMS OF ACTION
of cell therapies

Put into perspective
CLINICAL RESULTS
and current developments

Define CHALLENGES and
NEW MODELS of
market access

Rethink
PATIENT CARE
ORGANIZATION

Share BEST
PRACTICES